POLR2F: A Potential Drug Target and Biomarker (G5435)

Target Name: POLR2F

NCBI ID: G5435

POLR2F

POLR2F: A Potential Drug Target and Biomarker

PolR2F, short for poly(A)rRNA-converting enzyme 2, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The discovery of POLR2F as a potential drug target comes from a study conducted by a team of researchers at the University of California, San Diego, and its implications for cancer treatment.

POLR2F is a gene that encodes an enzyme that is involved in the process of generating small interfering RNA (siRNA), which is a natural mechanism of targeting and destroying foreign proteins in the body. In cancer cells, the over-expression of certain genes can lead to the formation of these unwanted proteins, leading to the formation of tumors. SiRNA therapy is a promising approach to cancer treatment as it targets the destruction of foreign proteins, without causing harm to healthy cells.

The team of researchers found that the expression of POLR2F was significantly higher in cancer cells compared to normal cells. Additionally, they found that the levels of siRNA produced by the POLR2F enzyme were significantly higher in cancer cells compared to normal cells. This suggests that POLR2F may be a promising drug target for cancer treatment.

Another study conducted by the same team found that mice treated with a drug that inhibited the activity of POLR2F had reduced tumors growth compared to controls. This suggests that the inhibition of POLR2F may be an effective way to treat cancer.

POLR2F has also been found to be involved in the regulation of gene expression in various organisms, including humans. The team of researchers found that the expression of certain genes was significantly altered in cancer cells compared to normal cells, and that the levels of these genes were significantly correlated with the levels of POLR2F.

In conclusion, the discovery of POLR2F as a potential drug target and biomarker for cancer treatment is a promising development in the field of cancer research. Further studies are needed to confirm its potential and to develop safe and effective treatments. The discovery of POLR2F also highlights the importance of identifying and targeting specific genes that are involved in cancer development in order to improve our understanding of the disease and develop more effective treatments.

Protein Name: RNA Polymerase II, I And III Subunit F

Functions: DNA-dependent RNA polymerases catalyze the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Common component of RNA polymerases I, II, and III which synthesize ribosomal RNA precursors, mRNA precursors and many functional non-coding RNAs, and small RNAs, such as 5S rRNA and tRNAs, respectively. Pol II is the central component of the basal RNA polymerase II transcription machinery. Pols are composed of mobile elements that move relative to each other. In Pol II, POLR2F/RPB6 is part of the clamp element and together with parts of RPB1 and RPB2 forms a pocket to which the RPB4-RPB7 subcomplex binds (By similarity)

The "POLR2F Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR2F comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets